Abogen Biosciences' Multi-KRAS mRNA Therapeutic Cancer Vaccine ABO2102 Receives FDA IND Approval

May 09, 2025 12:06 CST Updated 12:06

Abogen

Nucleic Acid Drug Developer

On May 9, 2025, Abogen announced that its self-developed novel mRNA cancer vaccine, which simultaneously covers multiple KRAS mutations, has officially received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application.Applicable to patients with solid tumors carrying any of the five common KRAS mutations.

This is the first therapeutic tumor vaccine in China targeting multiple KRAS mutations.，YesThe significant progress made in the highly challenging "undruggable" target field marks that Abogen Biosciences has risen to the ranks of global leaders in innovation within the tumor immunotherapy sector, demonstrating substantial international influence.

About KRAS Mutation

KRAS mutations are one of the most common oncogenic gene mutations in solid tumors and are often associated with malignant tumors: the incidence of KRAS mutations is as high as about 85% in pancreatic cancer, about 40% in colorectal cancer, and about 30% in non-small cell lung cancer. However, since its discovery in 1982, KRAS has long been considered an "undruggable" target due to the relatively smooth surface of its protein and the lack of a "pocket" for drug binding, among other unique properties.

Despite recent breakthroughs in KRAS G12C small-molecule inhibitors, limitations such as target specificity, inevitable drug resistance, and limited survival benefits still need to be addressed. There remains a significant unmet clinical need in the treatment of KRAS-mutant tumors.

Industry data show that in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC),Patients carrying these five common mutations account for a generally high proportion of KRAS-mutated patients, approximately 75%-85%.

This further highlights the urgency and clinical value of developing broad-spectrum KRAS-targeted therapies.

About ABO2102

ABO2102, a therapeutic cancer vaccine developed by Abogen based on its self-innovated mRNA technology platform, has demonstrated excellent anti-tumor activity in preclinical studies through multi-dimensional technological breakthroughs and achieved broad coverage of HLA (Human Leukocyte Antigen) subtypes. This vaccine provides a novel solution for the treatment of KRAS-mutant solid tumors, showcasing strong clinical transformation potential.

1. Multi-target Antigen Design

ABO2102 is an mRNA molecule that simultaneously encodes five common KRAS mutant antigens. After being translated into antigens within the cell, it is presented via MHC-I/II molecules, activating a dual immune response of CD8⁺ cytotoxic T cells and CD4⁺ helper T cells, enabling precise recognition and attack of KRAS mutant antigens. Compared to small-molecule inhibitors that only target the G12C mutation, ABO2102 can cover a broader range of KRAS mutation types.

2. Breakthrough in Drug Resistance Dilemma

Due to the single target and the difficulty in addressing the adaptive evolution of the tumor microenvironment, traditional KRAS G12C inhibitors have limited efficacy, with patients' median PFS (Progression Free Survival) typically being only 6-9 months. In contrast, ABO2102 can induce sustained expansion of specific T cells and establish long-term immune memory.

Preclinical data show that vaccine-activated T cells can precisely recognize neoantigens on the surface of KRAS-mutated cells and effectively kill tumor cells. This endogenous immune response not only avoids the off-target toxicity commonly associated with targeted drugs but also continuously suppresses tumor recurrence through immune memory mechanisms. Additionally, studies in mouse models indicate that ABO2102 combined with PD-1 monoclonal antibody has a synergistic effect, further enhancing anti-tumor efficacy.

3. Platform Empowering Drug Development

The development of ABO2102 is based on Abogen's mature tumor vaccine technology platform. First, the vaccine uses the LNP delivery system that has been extensively clinically validated during the COVID-19 pandemic, ensuring efficient mRNA delivery within cells and excellent safety. Second, the platform features modular antigen design capabilities, allowing flexible incorporation of different KRAS mutation antigen epitopes to quickly address various mutation types. It also employs next-generation mRNA sequence design, significantly enhancing immunogenicity. Meanwhile, the platform utilizes bioinformatics to predict and select high-coverage antigen epitopes.And it has been confirmed by preclinical experiments, showing a wide range of HLA coverage potential.

4. Promising Clinical Translation Prospects

ABO2102 is expected to shift the paradigm of KRAS-targeted therapy from "passive inhibition" to "active immune clearance," demonstrating breakthrough clinical value. This vaccine, based on a multi-epitope antigen design, precisely covers high-incidence tumor types such as pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Its modular technology platform further supports rapid expansion to other mutation-related indications. With the advantage of being an off-the-shelf product, ABO2102 can be used for salvage treatment in advanced patients as well as adjuvant therapy post-surgery in early-stage cases. Moreover, due to its excellent safety profile, the vaccine can be combined with chemotherapy, radiotherapy, or immune checkpoint inhibitors to establish a multidimensional synergistic cancer treatment system.

ABO2102 Successfully Obtains FDA IND Approval, Demonstrating Abogen's Breakthrough Progress in Traditionally Difficult Drug Targets, Showcasing the Company’s Innovation and Competitiveness in mRNA Drug Development, and Gaining Recognition from Global Regulatory Systems. In the Future, with the Continuous Advancement of Clinical Research, ABO2102 is Expected to Bring Breakthrough Treatment Options for Patients with KRAS Mutation-Related Tumors, Reshaping the Landscape of Tumor Immunotherapy.

About Us

Abogen Biosciences (referred to as "Abogen") is an innovative biopharmaceutical company dedicated to the research and development of messenger ribonucleic acid (mRNA) drugs. The company possesses industry-leading, proprietary mRNA and nanodelivery technology platforms, and is one of the few mRNA drug development enterprises in China with comprehensive value chain capabilities, covering all aspects from mRNA design, formulation development to large-scale production. Abogen has established a rich product pipeline spanning multiple fields, including infectious disease prevention and treatment (such as mRNA COVID-19 vaccines), cancer immunotherapy, and protein replacement therapies.